These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 19477372

  • 21. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1.
    Nomoto K, Oguchi S, Watanabe I, Kushiro T, Kanmatsuse K.
    J Cardiol; 2003 Nov; 42(5):201-6. PubMed ID: 14658408
    [Abstract] [Full Text] [Related]

  • 22. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography.
    Heslop CL, Frohlich JJ, Hill JS.
    J Am Coll Cardiol; 2010 Mar 16; 55(11):1102-9. PubMed ID: 20223364
    [Abstract] [Full Text] [Related]

  • 23. Markers of inflammation are inversely related to physical activity and fitness in sedentary men with treated hypertension.
    Hjelstuen A, Anderssen SA, Holme I, Seljeflot I, Klemsdal TO.
    Am J Hypertens; 2006 Jul 16; 19(7):669-75; discussion 676-7. PubMed ID: 16814119
    [Abstract] [Full Text] [Related]

  • 24. Inflammatory markers and cardiac function in acute coronary syndrome: difference in ST-segment elevation myocardial infarction (STEMI) and in non-STEMI models.
    Di Stefano R, Di Bello V, Barsotti MC, Grigoratos C, Armani C, Dell'Omodarme M, Carpi A, Balbarini A.
    Biomed Pharmacother; 2009 Dec 16; 63(10):773-80. PubMed ID: 19906505
    [Abstract] [Full Text] [Related]

  • 25. Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy.
    Blum A, Costello R, Samsel L, Zalos G, McCoy P, Csako G, Waclawiw MA, Cannon RO.
    Isr Med Assoc J; 2009 Oct 16; 11(10):602-5. PubMed ID: 20077946
    [Abstract] [Full Text] [Related]

  • 26. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ, Fang CH.
    Med Hypotheses; 2004 Oct 16; 62(4):499-506. PubMed ID: 15050096
    [Abstract] [Full Text] [Related]

  • 27. [Acute coronary syndrome and inflammation. Biomarkers for diagnostics and risk stratification].
    Trepels T, Zeiher AM, Fichtlscherer S.
    Herz; 2004 Dec 16; 29(8):769-76. PubMed ID: 15599673
    [Abstract] [Full Text] [Related]

  • 28. Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease.
    Hébert MJ, Masse M, Vigneault N, Sirois I, Troyanov S, Madore F.
    Am J Kidney Dis; 2001 Dec 16; 38(6):1271-6. PubMed ID: 11728960
    [Abstract] [Full Text] [Related]

  • 29. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E, PEACE Investigators.
    Circulation; 2007 Mar 27; 115(12):1528-36. PubMed ID: 17372173
    [Abstract] [Full Text] [Related]

  • 30. Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study.
    Hillis GS, Pearson CV, Harding SA, Sutherland S, Ludlam CA, Marioni JC, Prescott RJ, Fox KA, Flapan AD.
    Am Heart J; 2004 Jul 27; 148(1):72-9. PubMed ID: 15215794
    [Abstract] [Full Text] [Related]

  • 31. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.
    Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Münzel T, Yusuf S, HOPE Study Investigators.
    Circulation; 2006 Jul 18; 114(3):201-8. PubMed ID: 16831981
    [Abstract] [Full Text] [Related]

  • 32. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Dosh K, Berger PB, Marso S, van Lente F, Brennan DM, Charnigo R, Topol EJ, Steinhubl S.
    Circ Cardiovasc Interv; 2009 Dec 18; 2(6):503-12. PubMed ID: 20031767
    [Abstract] [Full Text] [Related]

  • 33. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS, Larsen AI.
    Tidsskr Nor Laegeforen; 2009 Jun 11; 129(12):1221-4. PubMed ID: 19521445
    [Abstract] [Full Text] [Related]

  • 34. Time-dependent changes of hs-CRP serum concentration in patients with non-ST elevation acute coronary syndrome.
    Jahn J, Hellmann I, Maass M, Giannitsis E, Dalhoff K, Katus HA.
    Herz; 2004 Dec 11; 29(8):795-801. PubMed ID: 15599677
    [Abstract] [Full Text] [Related]

  • 35. Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.
    Delhaye C, Sudre A, Lemesle G, Maréchaux S, Broucqsault D, Hennache B, Bauters C, Lablanche JM.
    Cardiovasc Revasc Med; 2009 Dec 11; 10(3):144-50. PubMed ID: 19595394
    [Abstract] [Full Text] [Related]

  • 36. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
    Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J, PEACE Investigators.
    Arterioscler Thromb Vasc Biol; 2007 Nov 11; 27(11):2463-9. PubMed ID: 17766330
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease.
    Almagor M, Keren A, Banai S.
    Am Heart J; 2003 Feb 11; 145(2):248-53. PubMed ID: 12595841
    [Abstract] [Full Text] [Related]

  • 39. Increased levels of atherosclerosis markers in salt-sensitive hypertension.
    Larrousse M, Bragulat E, Segarra M, Sierra C, Coca A, de La Sierra A.
    Am J Hypertens; 2006 Jan 11; 19(1):87-93. PubMed ID: 16461197
    [Abstract] [Full Text] [Related]

  • 40. Interaction between Chlamydia pneumoniae seropositivity, inflammation and risk factors for atherosclerosis in patients with severe coronary stenosis.
    Yavuz MT, Yavuz O, Yazici M, Guler S, Ozhan H, Albayrak S, Coskun A.
    Scand J Clin Lab Invest; 2006 Jan 11; 66(6):523-34. PubMed ID: 17000560
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.